pharmaceutical and biotechnology industries, and cancer research organizations from China and the United Sates (US) attended the meeting.
On behalf of the organizing committee, Dr. Yun-Guang Tong, Chair of the 2014 Annual Meeting ( Figure 1A Dr. Shi-Yuan Cheng, President of USCACA ( Figure 1B ), summarized key initiatives and accomplishments of USCACA. These included: (1) Collaborating with associations and organizations dedicated to cancer research, education, treatment and prevention, notably Chinese Anti-Cancer Association (CACA), CSCO, Chinese Society for Anti-Cancer Agents (CSACA), American Association for Cancer Research (AACR), ASCO, National Foundation for Caner Research (NFCR), and Asian Foundation for Cancer Research (AFCR); (2) Supporting Chinese Journal of Cancer (CJC), the official journal of USCACA, to achieve its milestone of being included in the Scientific Citation Index (SCI). USCACA will continue organizing special CJC issues on selected topics in 2014, including the second issue on Pollution and Cancer, and issues of Epstein-Barr Virus and Nasopharyngeal Carcinoma , Immunoncology , and Cancer Metabolism; and (3) Implementing and expanding USCACA-NFCR Scholarship Program. With the effort of the Scholarship Selection Committee led first by Dr. Shi-Yuan Cheng and then by Dr. Li-Fang Hou, during the past four years, 16 outstanding junior Chinese investigators have received this award [1] [2] [3] . Dr. Cheng also highlighted the growing influence of USCACA. USCACA was approached for opinion on the rising cancer rates in China, India, and Russia [4] by the American division of Chinese state broadcaster China Central Television (CCTV-America) (http://youtu.be/z5CybZIufQs).
After an introduction of the new initiatives of CSCO and the CSCO-USCACA Collaboration by Dr. Yi-Long Wu ( Figure 1C Chin J Cancer; 2014; Vol. 33 Issue 8 www.cjcsysu.com major challenge in sequencing genome of a single cell is to develop an approach for whole-genome amplification that recovers a high percentage of the genome with minimal amplification bias. This new technology recently developed in Dr. Xie's Lab, named as multiple annealing and looping-based amplification cycles (MALBAC), overcomes the shortcomings of the old methodologies and improves genome coverage from 60% to 93% and efficiency of detecting both alleles of known single-nucleotide variations from 10% to 71% [5, 6] . [7] . It was observed that every CTC from an individual patient, regardless of the cancer subtypes, exhibited reproducible copy number variation (CNV) patterns, similar to those of the metastatic tumor from the same patient. Different patients with lung cancer adenocarcinoma (ADC) shared similar CNV patterns in their CTCs. Patients of small-cell lung cancer have CNV patterns distinct from those of ADC patients. These findings also suggested that CNVs at certain genomic loci are selected for cancer metastasis. The reproducibility of cancer-specific CNVs offers potential for CTC-based cancer diagnostics and an additional means for improving clinical management of lung cancer patients.
Dr. Zong-Hui Peng, Deputy Director of Pharmacogenomics Research from Beijing Genomics Institute (BGI) Tech, introduced Multi-Omics Solutions for Cancer Research ( Figure 3B ). Dr. Peng highlighted the technical solutions and platforms developed by BGI Tech that would facilitate cancer research by taking advantage of various "-omics" technologies. In collaboration with Dr. Qi-Min Zhan at Chinese Academy of Medical Sciences and Peking Union Medical College, whole-genome sequencing, exome sequencing, and array comparative genomic hybridization analysis were recently used to explore the genomic alterations in esophageal squamous cell cancer (ESCC) [8] , one of the most aggressive cancers and the 6th leading cause of cancer death worldwide [9] . This collaboration led to identification of eight significantly mutated genes, of which six were well known tumour-associated genes (TP53, RB1, CDKN2A, PIK3CA, NOTCH1, and NFE2L2), and two previously unknown in ESCC (ADAM29 and FAM135B). In addition to the mutations, MIR548K, a microRNA encoded in the amplified 11q13.3-13.4 region, was found to be a novel oncogene. Other interesting findings included a frequent alteration in histone regulator genes, MLL2 (as known as KMT2D), ASH1L, MLL3 (KMT2C), SETD1B, CREBBP, and EP300. The study also highlighted that somatic aberrations in ESCC were mainly involved in the Wnt, cell cycle, and Notch pathways. These discoveries are expected to facilitate development of targeted therapy in ESCC. Figure 3C ), and Dr. Yi-Long Wu shared their clinical studies of personalized medicines in lung cancer treatment. In the Phase II/ III Biomarker-driven Master Protocol in second-line squamous lung cancer trial championed by SWOG and Cluster Trial being conducted at Guangdong General Hospital, lung cancer patients are first profiled for genetic aberrations and subsequently assigned to molecular targeted agents such as PI3K, CDK4/6, cMET, FGFR inhibitors to attack the specific corresponding genetic aberrations harbored in their tumors. By matching patients with appropriate targeted therapies, this approach is designed to expedite cancer drug development and to improve the success rate, ultimately leading to personalized medicine for cancer patients.
Dr. Michael Shi, Global Clinical Program Head, Novartis, and an Executive Member of the USCACA, hosted the panel discussion (Figure 4 ) on Genomic Medicine in Oncology R&D and Its Impact on Early Drug Development in China. Dr. Shi opened the discussion by briefly going over the background and last year's discussion on the topic [3] . He then raised questions to distinguished panelists from industry and academia included: Dr. Li Xu, USCACA Executive Committee, Senior Vice President of Hengrui Oncology; Dr. Roger Luo, USCACA Executive Committee, Director and Liaison of Asia 
